Arvinas, Inc. ARVN
Arvinas, Inc. (Nasdaq: ARVN) is an oncology drug developer. Its lead program, ARV-6723, is in Phase 1 for advanced solid tumors.
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| VEPPANU (vepdegestrant) | ER+/HER2-, ESR1-mutated advanced or metastatic breast cancer | small molecule | Approved |
| Luxdegalutamide (ARV-766) | metastatic castration-resistant prostate cancer | small molecule | Phase 3 |
| ARV-393 | relapsed/refractory NHL (B-cell and T-cell lymphomas) | small molecule | Phase 1 |
| ARV-027 | spinal bulbar muscular atrophy (SBMA) | small molecule | Phase 1 |
| ARV-6723 | advanced solid tumors | small molecule | Phase 1 |
| ARV-102 | Parkinson's disease, PSP | small molecule | Phase 1 |
| ARV-806 | advanced solid tumors with KRAS G12D mutations | small molecule | Phase 1 |
Recent results and decisions
- Nov 3, 2026started Arvinas initiated dosing in a Phase 1/2 trial of ARV-6723, an oral PROTAC HPK1 degrader, for advanced solid tumors.
Initiated dosing of patients in the monotherapy cohort of the Phase 1/2 clinical trial (ClinicalTrials.gov Identifier: NCT07749586) of ARV-6723, Arvinas' first immuno-oncology degrader.
Filing - Nov 3, 2026positive ARV-102 Phase 1 trial showed improved eye movement and biomarker changes in patients with Parkinson's disease.
Data showed improvements in an objective measure of impaired eye movement associated with Parkinson's disease. Changes in oculomotor function correlated with reductions in LRRK2 cerebrospinal fluid biomarkers and changes in synaptic biomarkers.
Filing - Nov 3, 2026n/a Arvinas plans to submit a clinical trial application for ARV-102 in PSP in the EU in Q4 2026 and in the UK in Q1 2027.
Submit clinical CTA to initiate Phase 1b trial in patients with PSP (EU 4Q 2026; UK 1Q 2027).
Filing
1 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 1 oncology companies
- Erasca, Inc. ERAS
- Parabilis Medicines, Inc. PBLS
- Xencor Inc XNCR
- Schrodinger, Inc. SDGR
- Vir Biotechnology, Inc. VIR
- Zymeworks Inc. ZYME
- Janux Therapeutics, Inc. JANX
- Aktis Oncology, Inc. AKTS
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.